- Conditions
- Smoldering Myeloma, Smoldering Multiple Myeloma
- Interventions
- Elotuzumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 79
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
- Interventions
- Sargramostim, BB-MPI-03, Montanide
- Drug
- Lead sponsor
- Benovus Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Fairfax, Virginia
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
- Interventions
- defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis
- Dietary Supplement · Genetic · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide
- Radiation · Drug · Procedure + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2019
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone, Carfilzomib, Daratumumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Monoclonal Gammopathy, Smoldering Multiple Myeloma
- Interventions
- Daratumumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 6
- States / cities
- Monterey, California • Denver, Colorado • Boston, Massachusetts + 1 more
- Conditions
- Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Plasma Cell Disorders
- Interventions
- Blood draw for the laboratory assessment
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,665 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Nivolumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- High Risk Smoldering Multiple Myeloma
- Interventions
- Ibrutinib
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Interventions
- Whole Foods Plant-based Diet, Algae Omega 3 + Curcumin, Placebo supplements
- Other · Dietary Supplement
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- TBL 12
- Drug
- Lead sponsor
- Jagannath, Sundar, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Revlimid, Dexamethasone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
- Interventions
- DKK1
- Biological
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 12 more
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 140
- States / cities
- Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Interventions
- Metformin XR, Placebo
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- PVX-410
- Biological
- Lead sponsor
- OncoPep, Inc.
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Niles, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Talquetamab, Daratumumab SC
- Drug
- Lead sponsor
- Carl Ola Landgren, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Elotuzumab (BMS-901608; HuLuc63)
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 12
- States / cities
- San Diego, California • New Haven, Connecticut • West Haven, Connecticut + 7 more
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Selinexor
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York